Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
Priced IPO
Solaredge Technologies, Inc. (SEDG)
The Marygold Companies (MGLD)
Blue Water Vaccines (BWV)
Meihua International Medical Technologies (MHUA)
Smart for Life (SMFL)
Vivakor (VIVK)
TC BioPharm Holdings (TCBP)
Direct Digital Holdings, Llc (DRCT)
Modiv (MDV)
Sky Technologies (SKYX)
Modular Medical (MODD)
HeartCore Enterprises (HTCR)
Arcellx, Inc. (ACLX)
Silver Spike Investment Corp. (SSIC)
Maris-Tech Ltd. (MTEK)
Yoshitsu Co., Ltd. (TKLF)
Tpg Inc. (TPG)
Hillstream BioPharma (HILS)
Hour Loop (HOUR)
Vigil Neuroscience, Inc. (VIGL)
More companies

Aura Biosciences, Inc. (AURA)

Sector - Healthcare

Price chart

N/A
Return from IPO

Company News

IPO Profile

About company

They are a clinical-stage biotechnology company leveraging their novel targeted oncology platform to develop a potential new standard of care across multiple cancer indications, with an initial focus on ocular and urologic oncology. Their proprietary platform enables the targeting of a broad range of solid tumors using Virus-Like Particles, or VLPs, that can be conjugated with drugs or loaded with nucleic acids to create Virus-Like Drug Conjugates, or VDCs. AU-011, their first VDC candidate, is being developed for the first line treatment of primary choroidal melanoma, a rare disease with no drugs approved. They have completed a Phase 1b/2 trial using intravitreal administration that has demonstrated a statistically significant growth rate reduction in patients with prior active growth and high levels of tumor control with visual acuity preservation in a majority of patients, as assessed using clinical endpoints in alignment with feedback from the U.S. Food and Drug Administration, or the FDA. These data supported advancement into a Phase 2 dose escalation trial, where they are currently evaluating suprachoroidal, or SC, administration of AU-011. They plan to present six to twelve month safety and efficacy data from this trial in 2022, and, if favorable, initiate a pivotal trial in the second half of 2022.
Industry
Pharmaceutical Preparations
CEO CFO
-
Employees Founded
42 2009

Contacts

Address: 85 Bolton Street Cambridge, Ma 02140

Telephone: (617) 500-8864

Web page: http://www.aurabiosciences.com

IPO information

First Trade Date 10/29/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 5
Shares Revised (MM) 5.4
Expected offer amount (MM) $75
Realized offer amount(MM) $75.6

Financial Data (last reporting year)

Market Cap (MM) $420.15
Revenues (MM) $0
Net Income (Loss) (MM) $-23.3

Voting

What do you think will happen with the AURA share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Cowen

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
Cowen/ SVB Leerink/ Evercore
CO-Managers
BTIG

Sector: Healthcare

Tweets about $AURA

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats